FDA, Dr Henry Miller, President Trump discussed on Dan Proft
To the show. We're speaking with Dr Henry Miller, physician and molecular biology senior fellow at the Pacific Research Institute. And he was the founding director of the F D. A s Office of biotechnology. And before we turn to a discussion of vaccines, a couple of things one Just on the matter of masks and stopping the spread. You know the suggestion from a lot of quarters, including Dr Roger Klein, former head of molecular on college he had Cleveland clinic is That we're not going to stop the spread masks aren't going to stop the spread. There's no really really science behind that contention, and so it's ultimately going to be a combination of people getting infected and a vaccine that gets us to herd immunity. Is that inaccurate? Well, I I think Herd immunity appears to be a natpe oration goal. But it doesn't seem to be in the cards for this currently, um the the percentage of people in the population who have been infected Given that it varies in different parts of the country is maybe 10%. And the vaccines have limitations of two kinds. One is that no vaccine it's 100% effective. Oh, and FDA has shut the bar 50% advocacy for to be approved. Uh, the other factor that's critical is the uptake. Find a population. And upwards of 50% of Americans at this point say that they want up to take the vaccine. And so if you have a say on 80% Affective taxes, but only half of the population. Take it. That's 80% 50% that gives you a 40% community. In the population from the vaccine, and that's just not enough for genuine herd immunity. It'll help to be sure. And I'm one of the great boosters of vaccine development on the White House's operation Warp speed, which was ah, brilliant exercise in getting the vaccine available more rapidly, much more rapidly. Then it would have been otherwise. But the vaccine is not going to be a kind of see it. We're going to need a CZ. Your quote earlier, said tto. Learn to live with this. In some sort of MotorCity, then that's acceptable to individuals and to the nation at large, just on the threshold of efficacy. Ah, I remember it correctly. I think, the CEO Fizer said. They would apply for FDA approval for their vaccine and development. If it proves out by and they should know by the end of October that it's effective 70% of the time. Is that is that an appropriate threshold to bring to the table for FDA approval, even though it says sensibly higher than the the threshold that the FDA is setting well, sure, 70% is a lot better. Then 50%, and it's interesting that the vaccine developing companies have been extremely responsible in this regard, but they put out an unprecedented statement that said That they wouldn't push for premature approval until they were absolutely certain of adequate safety and efficacy of other vaccines. 70% would be On an excellent taxi and 50% would be okay but still acceptable for, uh, preventing a disease that doesn't have a cure or another means of prevention, just going back to the herd immunity issue and the amount of the percent of the population that's been infected. This is this is a sort of an argument. But it wasn't an argument between inside and a silent fashion between Foulke between Atlas and then others jumped into on this notion of cross reactive immunity. And that it may be ah, significantly larger percentage of population that has some level of cross reactive immunity to the virus, then is otherwise borne out by the antibody testing that's been done to date and found she didn't like Scott Atlas criticizing Dr Redfield in public or disagreeing with him in public, But he really didn't dispute the fact that that could be true. And so I just wonder if if maybe we don't really have a handle on the The percentage of Americans who have been infected. Well way don't know that way. We don't know whether the virus is aware of that speculation or not. There's a lot unknown here. You know, we've described this as being in the fog of war, especially in the spring. And in many ways we're still there. Some of those data should come out. Of these very large vaccine trials because we'll see in the placebo group. How many infections there are placebos grouping me untreated. Good subjects being compared took vaccine treated, so we'll see what the incidences of them and get some idea of how Easy. It is how frequent it is to be infected. When you're not protected by a vaccine, a CZ you watched, and I mean, this is a little bit beyond their their scope. But Trump's medical team and all the attending coverage of President Trump testing positive for Cove. It Over the last 72 hours, basically, It seems to me the hope should be that President Trump and and everybody else infected with that high profile mean everybody infected generally, but for this limited purpose, everybody high profile associate the Trump campaign. Survives and I would and without too much incident, I would say the same if it was Biden and his team. Because number one. They're human beings. So you want people survive, But number two is that maybe it will disabuse some people of irrational fears of Overreactions trying to achieve this balance we were talking about when you see a 74 year old guy who's you know, not exactly. Jack Elaine. Able to get through to the other side of uninfected without too much incidents. The probabilities here are Are striking, but they're only probabilities you know at at at age 70 for the president has a three times higher likelihood of being hospitalized with Covert 19 infection on DH about five times greater. Probability than someone in his twenties of dying from it. So it's all probabilities, and a lot of the outcomes are factors that we don't understand. By the way, you mentioned his being at Walter Reed. There's an interesting tidbit here. The National Institutes of Health E, which is directly across the street from Walter Reed. And that's where Tony Sal trees offices and yet he hasn't been in evidence at all. In the president's character. I worked at an I age, so I know the area. Well, interesting. He is Dr Henry Miller, physician and molecular biologist, senior fellow at the Pacific Research Institute. He was the founding director of the F D. A s office of biotechnology. Dr Miller. Thanks as always, for joining us appreciate that's always.